01 — Evidence
Evidence Summary
Thymoquinone's evidence divides cleanly along one line: cell and animal work carries the tumour-suppression case, while the human record — genuinely real, RCT-anchored — speaks almost entirely to the body's side of treatment rather than to the tumour itself. Reading all three tiers together, rather than any one alone, gives the fairest picture.
Human
Clinical Record
Host-status RCTs; no antitumor endpoint tested
No trial has tested blackseed oil or thymoquinone against an established tumour. What exists instead is real: randomised trials showing reduced chemotherapy-induced phlebitis and oral mucositis, a chemoprevention signal in a premalignant lesion, and separate RCTs supporting hepatic, inflammatory, and stress-axis benefit.
Animal
Preclinical Signal
Five xenograft/metastasis models, one host-protective series
Tumour suppression or anti-metastatic activity is corroborated in vivo across breast, skin, gastric, lung, and bone-metastatic contexts — an unusually consistent in vivo record for a compound at this framework's depth. The same redox mechanism also protects normal neural, pulmonary, and cardiac tissue in three independent animal studies.
- Lung cancer stem-cell xenograft: slower tumour growth, reduced CD44/Nanog in situ
- Breast metastasis model: reduced lung, brain, and bone metastases via NF-κB/CXCR4
- Two xenografts (breast, skin): apoptosis confirmed with significantly reduced tumour growth relative to controls
- Nrf2/HO-1-mediated protection independently shown in neurons, lung, and heart tissue
In Vitro
Cell Model Data
STAT3/NF-κB convergent; human PK gap unresolved
STAT3 and NF-κB suppression are the two mechanistic throughlines running across every animal-corroborated finding above, extended further in myeloid leukaemia and colon cancer cell lines. No successful human pharmacokinetic profile exists to compare these effective concentrations against — a genuine gap, not a favourable one.
- STAT3 phosphorylation blocked via ROS-dependent Src inactivation
- NF-κB activation sequence blocked at IκBα kinase and p65 translocation
- Human NK-cell cytotoxicity against breast cancer cells significantly increased
- No successful human PK study exists to benchmark any of these concentrations against
Human
Clinical Record
No randomised trial has tested blackseed oil or thymoquinone against an established tumour — that is simply not a question the current human literature answers. What it does answer, with real RCT weight behind it, is the body's side of active cancer treatment. A single-blind trial in 60 cancer patients found that topical Nigella sativa oil, applied to the catheter site during the first three days of intravenous chemotherapy, significantly reduced phlebitis incidence and severity at later assessment points (60 and 72 hours) compared with no intervention.[7] A randomised trial in 54 acute myeloid leukaemia patients found a Nigella sativa oil mouth rinse, used through a 28-day induction chemotherapy course, attenuated chemotherapy-induced oral mucositis compared with a standard mouthwash control, with secondary reductions in salivary IL-6 and TNF-α.[8]
Continue reading — full research detail+
A randomised, placebo-controlled trial in 48 patients with oral leukoplakia — a potentially premalignant lesion, not active cancer — found mucoadhesive buccal tablets containing Nigella sativa extract (thymoquinone as its major active constituent, dosed at 5 or 10 mg/kg of extract) produced a statistically significant reduction in lesion size and in the proliferation marker Ki-67 compared with placebo over three months, without progression in the degree of dysplasia. This is a premalignant-lesion biomarker signal, not a demonstrated reduction in oral cancer incidence — the trial was neither powered nor followed long enough to determine whether malignant transformation was actually prevented.[9]
Three further human RCTs support host resilience during and beyond treatment, none oncology-specific but each satisfying this framework's disease-resilience inclusion test. A randomised, double-blind, placebo-controlled trial in 120 patients with non-alcoholic fatty liver disease found standardized Nigella sativa seed oil significantly reduced ultrasound-graded hepatic steatosis and serum ALT compared with placebo.[10] A randomised trial in 42 rheumatoid arthritis patients found a real but partial effect: the anti-inflammatory cytokine IL-10 rose significantly and oxidative-stress markers fell significantly, but TNF-α itself did not change.[21] A randomised trial in 72 healthy adults with non-restorative sleep found a standardized thymoquinone-rich extract significantly improved validated sleep-quality and stress scales, alongside significant cortisol, melatonin, and orexin modulation.[24]
Signal maturity: human evidence is real and RCT-anchored for host-status and disease-resilience outcomes across three distinct organ systems — but it is entirely silent on tumour response. Nobody should read the trials above as evidence this compound treats cancer; they simply don't ask that question.
Animal
Preclinical Signal
Seven independent xenograft or induced-metastasis animal models corroborate direct tumour-suppressive or anti-metastatic activity beyond cell culture — an unusually consistent in vivo record for a compound at this framework's depth. In a breast cancer xenograft model, thymoquinone suppressed tumour growth and induced apoptosis via p38 MAPK activation and ROS generation, and potentiated the antitumour effect of co-administered doxorubicin.[6] In an epidermoid carcinoma xenograft model in NOD scid gamma mice, thymoquinone suppressed tumour growth via the same ROS-mediated STAT3 suppression identified in its paired cell-culture arm.[1] In a breast-cancer intracardiac-injection metastasis model, thymoquinone significantly reduced lung, brain, and bone metastases via NF-κB-regulated downregulation of the chemokine receptor CXCR4.[18]
Continue reading — full research detail+
A gastric cancer model corroborates STAT3 suppression specifically, both in vivo and in vitro, in the same study.[2] In a lung-cancer xenograft built from tumorsphere-enriched cancer stem cells, thymoquinone slowed tumour growth and reduced CD44 and Nanog expression directly in the harvested tumour tissue, not only the originating cell culture.[16] A separate xenograft/allograft metastasis study found reduced tumour growth and reduced metastasis via suppression of the EMT master regulator TWIST1.[17] A seventh animal study, in a prostate xenograft model, confirms anti-angiogenic activity via AKT/ERK suppression, with tumour growth inhibited at low dosage and no observed chemotoxic side effects.[5]
Separately from oncology, the same redox mechanism protects normal host tissue in three independent animal contexts. In a rodent Parkinson's disease model, thymoquinone activated the Nrf2/ARE antioxidant pathway in dopaminergic neurons, reducing oxidative-stress-driven neurodegeneration, with the protective effect abolished by Nrf2 gene silencing — a mechanistically confirmed finding, not a correlation.[11] In rats with bleomycin-induced lung fibrosis, thymoquinone reduced inflammatory cytokines, oxidative markers, and fibrotic tissue changes through the same Nrf2/HO-1 axis.[22] In mice, thymoquinone pretreatment restored cardiac antioxidant enzyme activity and reduced serum markers of cardiac injury following doxorubicin-induced cardiotoxicity — directly relevant given doxorubicin's use as a chemotherapy agent.[23]
Signal maturity: direct tumour suppression or anti-metastatic activity is now corroborated in vivo across seven separate animal models spanning breast, skin, gastric, lung, and prostate cancer, and the same host-protective redox mechanism is independently corroborated in three non-oncology tissue contexts — a genuinely broad animal record for a compound of this framework's depth, though none of it has yet been tested against an established human tumour.
In Vitro
Cell Model Data
STAT3 suppression is additionally documented in myeloid leukaemia cell lines — both FLT3-ITD-positive AML cells and BCR-ABL-positive CML cells — where thymoquinone reduced phosphorylation of STAT3, STAT5, and JAK2, and separately downregulated PI3K, Akt, and mTOR expression while upregulating the tumour suppressor PTEN, in vitro only.[3] NF-κB pathway suppression is documented directly in human chronic myeloid leukaemia (KBM-5) cells, where thymoquinone inhibited sequential steps of NF-κB activation and enhanced apoptosis induced by TNF-α and chemotherapeutic agents.[4]
Continue reading — full research detail+
The same NF-κB mechanism separately chemosensitizes colon cancer cells to cisplatin, with reduced NF-κB-regulated VEGF, c-Myc, and Bcl-2 expression following thymoquinone treatment.[19] A human-cell, though not clinical, immune finding: co-culturing human natural killer cells with breast cancer cells in the presence of thymoquinone significantly increased NK-cell cytotoxic activity, with increased release of perforin, granzyme B, and interferon-α — the specific effector proteins responsible for NK-cell-mediated tumour killing, not just an overall activity readout.[20]
No successful human pharmacokinetic study for thymoquinone exists to compare any of these effective concentrations against — one exploratory attempt failed to detect the compound in human serum at all, detailed under Pharmacokinetics and Administration below. This is a genuine gap in the evidence base, not a favourable data point being read past.
Signal maturity: deepest mechanistic detail of any evidence tier here, and largely consistent with the animal-corroborated findings above — but the PI3K/Akt/mTOR, colon-cancer NF-κB, and NK-cell findings specifically have not yet been corroborated beyond cell culture.
Advertisement
02 — Pathways
Pathway Interaction Profile
Thymoquinone's pathway footprint is narrower than some compounds in this framework but unusually well corroborated for its size — most of its Key Pathways carry animal, not only cell-culture, evidence. What follows covers every pathway this compound's Research Brief supports with a real citation.
Thymoquinone's Contain classification is the strongest and best-corroborated role on this page — four independent Key Pathways, three of them confirmed in living tumours rather than cell culture alone, spanning breast, prostate, and lung cancer contexts.
Block Seeding & Niche Formation
Research concerning formation of supportive pre-metastatic niches at distant sites.
NF-κB / TNF-α / IL-6 inflammatory axis
Thymoquinone inhibits sequential steps of NF-κB activation — IκBα kinase activation, IκBα phosphorylation and degradation, p65 nuclear translocation — in human chronic myeloid leukaemia cells, enhancing apoptosis induced by TNF-α and chemotherapeutic agents.[4] The same mechanism chemosensitizes colon cancer cells to cisplatin, with reduced NF-κB-regulated VEGF, c-Myc, and Bcl-2 expression.[19] Critically, this mechanism is corroborated in vivo: in a breast-cancer intracardiac metastasis model, thymoquinone (2–4 mg/kg) significantly suppressed lung, brain, and bone metastases specifically via NF-κB-regulated downregulation of the chemokine receptor CXCR4, reducing osteolytic bone lesions and metastatic biomarkers.[18]
Angiogenesis / VEGF / HIF-1α
Thymoquinone inhibits human umbilical vein endothelial cell migration, invasion, and tube formation, suppressing AKT and extracellular signal-regulated kinase (ERK) activation downstream of VEGF signalling; in a xenograft human prostate cancer (PC3) model, thymoquinone blocked tumour angiogenesis in vivo and inhibited tumour growth at low dosage, without observed chemotoxic side effects and without directly inhibiting the VEGF receptor itself.[5]
Prevent Tumor Cell Shedding
Research concerning invasion and escape from existing lesions (EMT and ECM breach).
EMT & metastatic invasion
Thymoquinone decreases transcriptional activity of the TWIST1 promoter and TWIST1 mRNA expression, downregulating N-cadherin and upregulating E-cadherin; in cancer cell-derived xenograft tumours in mice, this translated into inhibited tumour growth and reduced metastasis, not only reduced in vitro invasiveness — an effect partially attenuated in TWIST1-overexpressed cell lines, confirming the mechanism's specificity rather than an off-target artefact.[17]
Prevent Dormant Reactivation
Research concerning wake-up signalling and reactivation of dormant disseminated tumour cells.
Cancer stemness (CD44, ALDH, Nanog/Sox2)
In lung-cancer tumorsphere-enriched cancer stem cells, thymoquinone significantly inhibited stem-like properties by promoting phosphorylation and ubiquitination of Yes-associated protein (YAP), downregulating the stemness markers CD44 and Nanog; in a xenograft model in nude mice using these same cancer stem cells, tumours in the thymoquinone-treated group grew significantly slower than controls, and immunohistochemistry confirmed reduced CD44 and Nanog expression directly in the harvested tumour tissue.[16]
Thymoquinone's Weaken classification rests on STAT3 suppression alone, but that single pathway carries the broadest independently-corroborated cancer-type spread of anything on this page — confirmed in vivo across two structurally unrelated cancer types before even counting the leukaemia cell-culture data.
Expansion Suppression
Research concerning proliferation, cell-cycle progression, and the capacity of lesions to add durable mass.
JAK/STAT (STAT3)
Thymoquinone induces ROS-dependent inactivation of Src kinase, which blocks phosphorylation and DNA-binding activity of STAT3, attenuating expression of STAT3 target genes cyclin D1 and survivin; in an epidermoid carcinoma xenograft model in NOD scid gamma mice, this mechanism was confirmed to suppress tumour growth in vivo, not only in the paired cell-culture arm.[1] A structurally unrelated study in gastric cancer cell lines confirmed thymoquinone suppresses proliferation via the same STAT3 pathway, corroborated in both in vitro and in vivo arms of the same study.[2] A third study in myeloid leukaemia cell lines found thymoquinone significantly inhibited phosphorylation of STAT3, STAT5, and JAK2 — in vitro only, no animal corroboration identified for the leukaemia context specifically.[3]
Thymoquinone's Attack classification is corroborated by the strongest evidentiary pattern this framework recognises short of human data: two independent xenograft mouse models, each showing measurable tumour growth suppression in vivo rather than cell-culture cytotoxicity alone.
Direct Tumor-Directed Killing
Research concerning regulated tumour-cell death (apoptosis, ferroptosis, necroptosis).
Intrinsic apoptosis (mitochondrial / Bcl-2)
In a breast cancer xenograft mouse model, thymoquinone induced p38 MAPK phosphorylation and ROS production, driving tumour-suppressive apoptosis in vivo and potentiating the antitumour effect of co-administered doxorubicin in the same model.[6] In an epidermoid carcinoma xenograft model, thymoquinone-induced apoptosis was associated with p53 induction, Bax upregulation, Bcl-2/Bcl-xL/Mdm2 downregulation, and activation of caspase-9, -7, and -3 — mechanistically downstream of the same ROS/STAT3 suppression pathway documented under Weaken above, since ROS generation was shown to be the initiating event for both.[1]
Thymoquinone's Protect classification carries real evidence in both sub-scopes. Oncology Host-Status covers clinical-outcome evidence tied specifically to cancer treatment, detailed below rather than carrying a pathway card by design. Disease-Resilience covers mechanism-based evidence that thymoquinone supports the body's own tissue resilience, independent of any specific drug interaction — and here it carries real cited findings across six separate mechanism categories, including a notable cross-study redox pattern detailed below.
Oncology Host-Status
Chemotherapy combination / peri-treatment timing — topical application of Nigella sativa oil to the intravenous catheter site, twice daily for the first three days of chemotherapy, significantly reduced phlebitis incidence and severity at later assessment points (60 and 72 hours) in a single-blind clinical trial of 60 cancer patients, compared with no intervention.[7]
Symptom burden improvement — a Nigella sativa oil mouth rinse, used four times daily throughout a 28-day induction chemotherapy course, attenuated the progression of chemotherapy-induced oral mucositis in 54 acute myeloid leukaemia patients compared with a standard mouthwash control, with secondary reductions in salivary IL-6 and TNF-α.[8]
Premalignant-lesion biomarker signal — in a randomised, placebo-controlled trial of 48 patients with oral leukoplakia (a premalignant lesion, distinct from active chemotherapy), mucoadhesive buccal tablets containing Nigella sativa extract (thymoquinone as the major active constituent) produced a statistically significant reduction in lesion size and in the Ki-67 proliferation marker compared with placebo over three months — the trial was not powered or followed long enough to establish whether malignant transformation was prevented.[9]
Hepatic Resilience & Clearance
Human and preclinical research on hepatic enzyme systems, bile-acid handling, and liver-related markers.
Hepatic steatosis and transaminase reduction
In a randomised, double-blind, placebo-controlled trial of 120 patients with non-alcoholic fatty liver disease, fully standardized Nigella sativa seed oil significantly reduced ultrasound-graded hepatic steatosis and serum ALT compared with placebo, alongside favourable shifts in triglycerides, LDL-C, and HDL-C, with no significant adverse safety findings reported over the trial period.[10] Human randomised controlled trial — the strongest evidence tier this framework recognises. Conflict-check: independent — no mechanistic link was established this session between this hepatic finding and any Contain/Weaken/Attack claim on this page.
Host-Selective Redox Buffering
Studies evaluating whether normal host tissues can be protected from oxidative stress selectively.
Nrf2/ARE-mediated antioxidant activation in host tissue
In a rodent model of Parkinson's disease and paired in vitro neuronal experiments, thymoquinone significantly reduced oxidative-stress-driven cell death and elevated nuclear translocation of Nrf2, increasing expression of downstream antioxidant genes (heme oxygenase-1, NQO1, glutathione-S-transferase); silencing Nrf2 abolished the protective effect, confirming the mechanism is Nrf2-dependent rather than incidental.[11]
A notable cross-study redox pattern
This is the dual-citation case this framework is built to surface, though it is worth being precise about what kind of evidence this is: no single study demonstrates thymoquinone acting on both tumour and host tissue in the same experimental system. Separate preclinical studies suggest context-dependent redox effects — ROS-associated pro-oxidant apoptosis in the tumour models cited under Attack above (see the Intrinsic apoptosis entry, cited [1,6]), and Nrf2/HO-1-associated antioxidant protection in non-malignant tissue models, independently corroborated in two further host-tissue contexts (pulmonary and cardiac) immediately below. This is a cross-study interpretation this framework draws to flag a pattern worth watching, not a directly demonstrated cell-selective mechanism — whether thymoquinone reliably produces both effects simultaneously in the same human body has not been established.
Other Organ-System Reserve
Research concerning renal, cardiac, pulmonary, and other non-hepatic organ reserve under stress.
Pulmonary and cardiac protection
In rats with bleomycin-induced lung fibrosis, thymoquinone reduced inflammatory cell counts, cytokine levels, and biochemical markers of oxidative stress in bronchoalveolar lavage fluid, and reduced fibrotic markers (TGF-β, hydroxyproline) and apoptotic markers in lung tissue, tied to modulation of the Nrf2/HO-1 signalling pathway.[22] In mice, thymoquinone pretreatment significantly reduced serum markers of cardiac injury (AST, creatine kinase-MB, LDH) and restored antioxidant enzyme activity following doxorubicin-induced cardiotoxicity — directly relevant given doxorubicin's use as a chemotherapy agent.[23] Two independent animal studies, two organ systems, one directly modelling a chemotherapy-injury context. Conflict-check: independent with respect to any Contain/Weaken/Attack claim on this page — though the pulmonary finding shares the same Nrf2/HO-1 axis as Host-Selective Redox Buffering above, a third independent host tissue carrying the same protective mechanism.
Immune Competence (Surveillance)
Research concerning immune recognition, surveillance, and cytotoxic capacity in the host.
Enhanced natural killer cell cytotoxicity
Co-culturing human natural killer (NK) cells with breast cancer cells in the presence of thymoquinone significantly increased NK-cell cytotoxic activity against the tumour cells, with increased release of perforin, granzyme B, and interferon-α — the specific effector proteins responsible for NK-cell-mediated tumour killing.[20] In vitro (human cells) only; no animal or clinical corroboration identified.
Inflammatory Regulation
Human and preclinical research on systemic inflammatory regulation, distinct from immune-cell surveillance and organ-specific injury.
Mixed effect on systemic inflammatory markers
In a randomised, double-blind, placebo-controlled trial of 42 rheumatoid arthritis patients, the anti-inflammatory cytokine IL-10 rose significantly, and the oxidative-stress markers malondialdehyde and nitric oxide fell significantly from baseline. TNF-α, superoxide dismutase, catalase, and total antioxidant capacity showed no significant between- or within-group difference.[21] A real human RCT, but the effect is partial, not comprehensive — stated at that precision rather than summarised as a general anti-inflammatory finding.
Neuroendocrine / Sleep / Stress Axis
Human and preclinical research on neuroendocrine, sleep, and stress-axis regulation in the host.
Sleep quality and stress-axis modulation
In a randomised, double-blind, placebo-controlled trial of 72 healthy adults with self-reported non-restorative sleep, a standardized thymoquinone-rich black cumin oil extract produced significant improvement on the Pittsburgh Sleep Quality Index and Perceived Stress Scale compared with placebo, alongside significant modulation of serum cortisol, melatonin, and orexin levels.[24] Evidence-independence note: this trial used a standardized proprietary extract (BlaQmax®), not plain culinary or generic standardized oil, and several authors were affiliated with the ingredient's manufacturer; the authors disclosed this as a conflict of interest in the published paper, and independent replication by an unaffiliated group has not been identified.
Block Seeding & Niche Formation
Research concerning formation of supportive pre-metastatic niches at distant sites.
NF-κB / TNF-α / IL-6 inflammatory axis
Thymoquinone has been reported to block the signalling step tumour cells use to sustain inflammatory survival and spread — the only pathway on this page corroborated across three separate cancer contexts, one of them confirmed in a living metastasis model rather than cell culture alone.
Prevent Tumor Cell Shedding
Research concerning invasion and escape from existing lesions (EMT and ECM breach).
Thymoquinone has been reported to suppress the master regulator tumour cells use to detach and spread, confirmed in a living xenograft model with both slower tumour growth and reduced metastasis — not only reduced invasiveness in a dish.
Prevent Dormant Reactivation
Research concerning wake-up signalling and reactivation of dormant disseminated tumour cells.
Cancer stemness (CD44, ALDH, Nanog/Sox2)
Thymoquinone has been reported to reduce cancer-stem-cell markers in a lung tumour model, confirmed both by slower tumour growth in living mice and by direct tissue analysis of the harvested tumour itself.
Expansion Suppression
Research concerning proliferation, cell-cycle progression, and the capacity of lesions to add durable mass.
Thymoquinone has been reported to block a signalling pathway tumour cells depend on to keep growing, confirmed in vivo across two structurally unrelated cancer types — the broadest independently-corroborated cancer-type spread of any pathway on this page.
Direct Tumor-Directed Killing
Research concerning regulated tumour-cell death (apoptosis, ferroptosis, necroptosis).
Intrinsic apoptosis (mitochondrial / Bcl-2)
Confirmed directly in two independent living tumour models (breast and skin): thymoquinone induces oxidative-stress-driven cell death accompanied by significantly reduced tumour growth relative to controls — smaller final tumour volume, not necessarily regression from baseline. The strongest evidentiary pattern this framework recognises short of human data.
Host-Selective Redox Buffering
Studies evaluating whether normal host tissues can be protected from oxidative stress selectively.
Nrf2-mediated protection of normal tissue
Separate preclinical studies suggest thymoquinone's redox-modulating activity works in opposite directions depending on cellular context — pro-oxidant and tumour-killing in tumour models, antioxidant and protective in three independent normal-tissue models (neurons, lungs, heart). This cross-study pattern is worth flagging, but no single study has directly demonstrated both effects together in the same system.
Hepatic Resilience & Clearance
Human and preclinical research on hepatic enzyme systems, bile-acid handling, and liver-related markers.
Hepatic steatosis and transaminase reduction — a randomised, placebo-controlled human trial found standardized oil significantly reduced hepatic steatosis and liver enzyme levels in patients with non-alcoholic fatty liver disease.
Neuroendocrine / Sleep / Stress Axis
Human and preclinical research on neuroendocrine, sleep, and stress-axis regulation in the host.
Sleep quality and stress-axis modulation — a randomised human trial found a standardized extract significantly improved sleep-quality and stress scores, alongside real hormonal changes in cortisol, melatonin, and orexin.
Advertisement
03 — Pharmacokinetics
Pharmacokinetics and Administration
The honest headline here is a gap, not a finding: no successful human pharmacokinetic profile for thymoquinone has been established. What follows is animal PK data, one exploratory human attempt that failed to detect the compound at all, real human dosing precedent from the trials already described above, and a documented in vitro drug-interaction signal that doesn't depend on the PK gap to matter.
Absorption
No successful human absorption data exists — one exploratory attempt failed to detect the compound in serum at all. In a rabbit model, oral thymoquinone showed absolute bioavailability of approximately 58%, with an absorption half-life of ~217 minutes and a ~23 minute lag time. This is animal data standing in for a real human gap.
The Concentration Gap
No defensible human comparison can be made. The one attempt to measure thymoquinone in human serum after oral oil ingestion failed to detect it at all. Animal data alone hints that doses already used in trials aren't an unreasonable starting point, but that is an inference, not a measured human result.
Clinical Dose Context
Human trials span 200 mg/day to ~5 mL/day of standardized oil or extract, each matched to its own clinical question rather than a shared reference dose — from topical peri-chemotherapy application to 90-day oral supplementation.
Metabolism
Thymoquinone inhibits CYP1A2, CYP2C9, CYP2D6, and CYP3A4 in human liver microsomes, concentration-dependently — CYP2C9 is the most sensitive at low concentration.
Co-Dosing Considerations
In vitro competitive inhibition of CYP2C9 creates a plausible interaction risk with warfarin and phenytoin — kinetically modelled, but not yet confirmed in a clinical coadministration study.
Formulation
Sold and studied mainly as whole seed oil standardized to a declared thymoquinone content. Human trials used oral, topical, and buccal-tablet routes for different endpoints — no head-to-head formulation comparison exists.
Absorption
No successful human pharmacokinetic study for thymoquinone or blackseed oil has been established — a genuine gap, not an oversight. One exploratory attempt exists: a validated GC-MS assay, sensitive enough to reliably detect thymoquinone spiked into human serum down to microgram-per-millilitre levels, was applied to two healthy volunteers after oral ingestion of concentrated Nigella sativa oil (1 g and 3 g respectively) — neither thymoquinone nor its derivatives were detectable in their serum at all.[29] That result doesn't prove absorption doesn't happen; it means no usable human Cmax, half-life, or bioavailability figure currently exists, and the compound may be harder to detect and quantify in human serum than in animal models. The only pharmacokinetic dataset available comes from a rabbit model: following oral administration (20 mg/kg), thymoquinone showed an absorption half-life of approximately 217 minutes and an absolute oral bioavailability of approximately 58%, with a lag time of approximately 23 minutes and protein binding greater than 99%.[12] Thymoquinone's poor water solubility is broadly understood to make fat co-administration relevant, consistent with its delivery as an oil, though no figure specific to fat co-administration was identified.
The Concentration Gap
No defensible human concentration-gap comparison can currently be made. The comparison this subsection normally runs — in vitro effective concentration against actual achieved human plasma exposure — requires a real human plasma-concentration figure to anchor it, and none exists. If anything, the evidence points the other way: the one exploratory attempt to measure thymoquinone in human serum after oral oil ingestion, described under Absorption above, failed to detect the compound at all, using an assay validated as sensitive enough to find it if it were there.[29]
What can be said, at a much lower confidence level, comes from animal data alone. The gastric cancer study behind this page's STAT3 pathway entry tested thymoquinone across 10–125 μmol/L, with proliferation-suppressing and pro-apoptotic effects reported across that range.[2] A rat oral pharmacokinetic study — the same 20 mg/kg oral dose used in the rabbit PK study cited under Absorption, run independently in a second species — measured actual peak plasma concentration directly: 4.52 μg/mL in male rats and 5.22 μg/mL in female rats, equivalent to roughly 27–32 μmol/L, overlapping the lower portion of that in vitro range.[27] That is an animal-to-animal comparison and nothing more; it says nothing about what a human oral dose would achieve.
On the temptation to convert this into a human dose: the standard FDA/Reagan-Shaw body-surface-area method can convert the 20 mg/kg rat dose into a human-equivalent dose — approximately 195 mg for a 60 kg adult[28] — and that figure happens to land close to the 200 mg/day already used in two human RCTs on this page.[24,25] That alignment is worth noting, but it cannot be read as evidence those trials achieved the rat study's plasma concentration. Body-surface-area scaling estimates an equivalent dose, not an equivalent plasma concentration — it says nothing about absorption, first-pass metabolism, or protein binding, all of which determine what actually ends up in blood, and thymoquinone's protein binding is already known to exceed 99% in the one animal study that measured it.[12] The failed human serum-detection study above is a real, if small, signal that this translation may not hold at all for this specific compound.
The honest bottom line: human plasma exposure after an oral dose of thymoquinone remains unknown. A dedicated human pharmacokinetic study, using an assay capable of actually detecting the compound in serum, is the only thing that would close this gap. It does not currently exist, and one documented attempt has already come back empty.
Clinical Dose Context
No single dose is established across the human trials described above — each matched a dose and route to its own clinical question, not a shared reference point.
| Context | Dose / Route | Duration | Source |
|---|---|---|---|
| NAFLD (hepatic outcome) | 2.5 mL standardized oil, oral, q12h | 3 months | [10] |
| Chemo-induced phlebitis prevention | 5 drops oil, topical, BID | First 3 days of chemo | [7] |
| Chemo-induced oral mucositis | 10 mL oil, oral rinse, 4×/day | 28-day chemo course | [8] |
| Oral leukoplakia chemoprevention | Buccal tablets, 5–10 mg/kg | 3 months | [9] |
| Rheumatoid arthritis | 500 mg oil, oral, BID | 8 weeks | [21] |
| Sleep / stress (standardized extract) | 200 mg/day | 90 days | [24] |
| Phase I safety RCT | 200 mg/day, standardized extract | 90 days | [25] |
| Case report — serious adverse event | ~2000 mg/day, oral | 1 month | [15] |
No figure for dosing frequency or split-dose requirement grounded in human t½ data can be stated — no successful human PK study exists to derive one from. See Absorption above.
Metabolism
Thymoquinone is metabolized substantially through hepatic cytochrome P450 enzymes. In human liver microsomes, thymoquinone inhibited the metabolic activity of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 in a concentration-dependent manner, with CYP2C9 showing the greatest sensitivity at low concentrations (46.4% inhibition at 1 μM) and CYP1A2 and CYP3A4 showing the greatest inhibition at high concentrations (81.9% and 79.2% respectively at 100 μM).[13] A dedicated kinetic study confirmed thymoquinone is a competitive inhibitor of CYP2C9-mediated phenytoin hydroxylation (Ki = 4.45 ± 0.51 μM), with in vitro-in vivo extrapolation predicting a clinically meaningful herb-drug interaction risk at common intake levels.[14]
Formulation
Blackseed oil is sold and studied primarily as whole Nigella sativa seed oil standardized to a declared thymoquinone content, distinct from culinary (non-standardized) oil and from isolated/nanoparticle thymoquinone research formulations. The human trials described on this page used several routes for the same base material — oral (as a standardized oil taken directly[10], as a standardized proprietary extract[24], or as a Nigella sativa extract buccal tablet[9]) and topical (applied directly to skin/catheter site[7] or as an oral mucosal rinse[8]) — each matched to its trial's specific endpoint rather than reflecting one preferred delivery form. No head-to-head formulation comparison study was identified.
Co-Dosing Considerations
Thymoquinone's enzyme inhibition creates real interaction risk across a narrower set of categories than a compound with a larger clinical footprint, but the CYP2C9 finding specifically is kinetically well characterised, not merely theoretical. Each row is flagged by the most cautious guidance its cited evidence supports.
Discuss whether to combine, separate, or avoid blackseed oil and a medication with your treating oncology team or physician.
| Flag | Interaction |
|---|---|
| Avoid | Warfarin and other CYP2C9-metabolized anticoagulants — in vitro competitive CYP2C9 inhibition with low-micromolar Ki/IC50 values, and in vitro-in vivo extrapolation predicting a clinically relevant interaction risk at common intake levels. This is a mechanistic and modelled signal, not a clinical interaction study; CYP2C9 is the most concentration-sensitive of the four enzymes tested, with maximal inhibition already apparent at the lowest concentration tested.[13,14] |
| Caution | Phenytoin and other CYP2C9-metabolized antiepileptics — direct kinetic confirmation of competitive inhibition of phenytoin hydroxylation by thymoquinone (Ki = 4.45 μM).[14] |
| Caution | CYP3A4-metabolized medications broadly, including many chemotherapy agents, calcium channel blockers, and immunosuppressants — up to ~79% inhibition at higher concentration in human liver microsomes; a mechanistic signal, not a clinical interaction study.[13] |
| Caution | CYP1A2- and CYP2D6-metabolized medications — concentration-dependent inhibition documented, generally weaker than the CYP2C9/CYP3A4 effect at lower concentrations.[13] |
Advertisement
04 — Onset & Washout
Onset and Washout
There is no human onset or washout profile for thymoquinone to report — this section states that gap plainly rather than dressing up the one dataset that does exist as more than it is.
Absorption Timing
Figures from a rabbit oral-dosing study only — no human onset data exists to confirm or contradict this timeline.
Elimination
Same rabbit study. No human elimination half-life has been established.
Accumulated Effect
No data exists on how long downstream pathway effects take to emerge or persist with repeated dosing.
Dosing Pattern in Studies
No dosing-pattern conclusion can be drawn honestly from the data that exists.
Washout
No human washout window has been established for thymoquinone or blackseed oil.
No trial-design precedent, human or otherwise, was identified for how long thymoquinone's influence takes to clear before it stops being a relevant factor around a new medication or procedure.
The Only Clock This Compound Has
Most compounds in this framework can be read on two timelines — a fast, direct-pharmacology clock and a slower, downstream-phenotype clock. Thymoquinone can't be, honestly, because only one dataset exists at all, and it's an animal one. What follows is what that single study actually measured, stated plainly rather than extrapolated into a fuller picture than the evidence supports.
In a rabbit model, following oral administration (20 mg/kg), thymoquinone showed an absorption lag time of approximately 23 minutes, an absorption half-life of approximately 217 minutes, and an elimination half-life of approximately 274.6 minutes (~4.6 hours), with absolute oral bioavailability of approximately 58% and protein binding greater than 99%.[12] No successful human study — PK, onset, or otherwise — exists to compare this against; the one exploratory human serum attempt described under Pharmacokinetics and Administration failed to detect the compound at all. No downstream pathway effect (STAT3 suppression, NF-κB inhibition, Nrf2 activation) has been separately timed on its own clock the way this framework does for better-characterised compounds.
| Parameter | Value (rabbit, oral 20 mg/kg) |
|---|---|
| Absorption lag time | ~23 minutes |
| Absorption half-life | ~217 minutes |
| Elimination half-life (oral) | ~274.6 minutes (~4.6 h) |
Dosing Pattern in Studies
No dosing-pattern conclusion — continuity use, pulse-credible use, or anything between — can be honestly drawn from a single animal PK study with no downstream pharmacodynamic timing data attached to it. The mechanistic case documented under Pathway Interaction Profile above is real, but nothing in the evidence base speaks to how often or on what schedule that mechanism needs to be re-triggered to matter.
Washout
No human washout window has trial-design precedent for thymoquinone or blackseed oil, positive or negative. This is a genuine, unfilled gap rather than a figure this Brief chose not to include — nothing was found to report. A case report of rhabdomyolysis, acute kidney injury, and hepatotoxicity followed ingestion of approximately 2000 mg/day of a black seed oil product for one month — a higher nominal product dose than the standardized-extract RCTs described on this page, though differences in formulation and thymoquinone content prevent a direct, apples-to-apples dose comparison across products.[15] That case is a single serious event, not a controlled maximum-tolerated-dose finding, and shouldn't be read as either a safety ceiling or a washout marker. Anyone planning to introduce or discontinue thymoquinone around another medication or a procedure should raise it with their care team directly rather than relying on any specific window — none has been established.
Advertisement
05 — Safety
Safety Profile
Blackseed oil is generally well tolerated at the doses tested in RCTs, but a real serious-event case report at a substantially higher, longer-duration dose, alongside an in vitro-confirmed CYP2C9 interaction signal, both carry more weight in an oncology context than in general use.
Mild gastrointestinal upset — diarrhoea, borborygmi/burping, and an aftertaste of the oil in a minority of patients at RCT-level dosing; no liver enzyme changes accompanied it.
Rare but serious risk — a case report of rhabdomyolysis, acute kidney injury, and hepatotoxicity at approximately 2000 mg/day of a black seed oil product for one month, a higher nominal dose than the standardized-extract RCTs on this page, though formulation differences limit direct comparison.
CYP2C9-mediated drug interactions — confirmed in vitro and kinetically modelled as clinically plausible; warfarin and phenytoin are the clearest concerns, though no clinical interaction study has yet confirmed the magnitude of risk.
No formal contraindication established — pregnancy, hepatic/renal impairment, and anticoagulant-use caution are mechanistically reasonable but not formally confirmed in a primary human source.
Adverse Effects in Human Trials
The randomised controlled trial described under Pathway Interaction Profile's Hepatic Resilience entry (120 NAFLD patients, 2.5 mL every 12 hours for 3 months) reported no significant adverse safety findings and concluded the oil "seems to be safe" at that dose and duration.[10] A dedicated phase I safety RCT (70 healthy adults, a thymoquinone-rich black cumin oil, 200 mg/day for 90 days; authors affiliated with the ingredient manufacturer, disclosed as a conflict of interest in the paper) reported no serious adverse events; two participants developed mild diarrhoea, and six reported borborygmi and burping with an aftertaste of the oil, at different points during the 90-day period, with no significant change in serum ALT, AST, or alkaline phosphatase.[25]
Commonly reported effects, at a lower evidence tier worth stating precisely: the NIH's LiverTox database — a compiled reference, not a clinical trial in its own right — lists side effects of black cumin as abdominal discomfort, bloating, dysgeusia, diarrhoea, and headache, describing them as "generally transient and mild," with rash and hypersensitivity reactions as rare, potentially severe events.[26] Included because it corroborates and extends the phase I RCT finding above, but read at its actual tier: a synthesized reference summary, not a single controlled study with its own numbers to report.
Rare but Serious Risk
A case report described a 26-year-old male who developed rhabdomyolysis, acute kidney injury, and hepatotoxicity following ingestion of approximately 2000 mg/day of a black seed oil product for one month — a higher nominal product dose and longer duration than the standardized-extract RCTs described on this page, though differences in formulation and thymoquinone content prevent a direct dose comparison across products. The authors concluded black seed oil ingestion should be considered in the differential diagnosis for these conditions in patients presenting with unexplained rhabdomyolysis, acute kidney injury, or hepatotoxicity, and noted that adverse-effect data for black seed oil in the literature remains limited overall.[15]
No FDA/EMA warning or formal drug-induced liver injury (DILI) registry entry specific to blackseed oil or thymoquinone was identified. No absolute contraindication has cleared independent verification in a primary human source — caution around pregnancy, pre-existing liver or kidney impairment, and concurrent anticoagulant use is mechanistically reasonable given the case report and the CYP2C9 interaction profile below, but is not formally established.
Drug Interactions
Thymoquinone's CYP2C9 inhibition is confirmed in human liver microsomes, and in vitro-in vivo extrapolation predicts a potentially clinically relevant interaction with phenytoin specifically. Caution is therefore warranted with warfarin, phenytoin, and other sensitive CYP2C9 substrates, although no clinical coadministration study with black seed oil has established the actual magnitude of this risk in patients. Full drug-by-drug guidance, grouped by level of caution required, is set out under Co-Dosing Considerations in Pharmacokinetics and Administration above rather than repeated here.
06 — Sourcing
Sourcing Guide
Standardization to a declared thymoquinone content is the main factor separating a product that reflects the research above from generic culinary black seed oil. Our Sourcing Guide offers a curated list of products available on the retail market we found to answer that concern, alongside brand quality and accessibility.
Blackseed Oil Sourcing Guide07 — Literature
References
Last reviewed: July 2026